Squamous Cell Carcinomas of the Head and Neck in Fanconi Anemia: Risk, Prevention, Therapy, and the Need for Guidelines

Abstract

Fanconi anemia (FA) is a rare recessive DNA repair disorder that is clinically characterized by congenital malformations, progressive bone marrow failure, and increased incidence of malignancies, especially acute myeloid leukemia and squamous cell carcinomas of the head and neck (HNSCCs) and the anogenital regions. On a cellular level, typical features of the disorder are a high degree of genomic instability and an increased sensitivity to bi-functionally alkylating agents. So far, germ-line defects in 15 different FA genes have been identified. Some of these FA genes are also established as tumor susceptibility genes for familiar cancers.

In recent years, the prevention and therapy of HNSCCs in FA patients has become more important as the percentage of patients surviving into adulthood is rising. HNSCCs appear in very young FA patients without common risk factors. Since cisplatin-based chemotherapy in combination with radiotherapy, essential parts of the standard treatment approach for sporadic HNSCCs, cannot be used in FA patients due to therapy-associated toxicities and mortalities even with reduced dosing, surgery is the most important treatment option for HNSCCs, in FA patients and requires an early and efficient detection of malignant lesions. So far, no uniform treatment protocol for the management of HNSCCs in FA patients exists. Therefore, we propose that the information on affected FA patients should be collected worldwide, practical therapeutic guidelines developed and national treatment centers established.

Zusammenfassung

Die Fanconi-Anämie (FA) ist eine seltene rezessive DNA-Reparaturerkrankung, die klinisch durch angeborene Fehlbildungen, fortschreitendes Versagen des Knochenmarks und ein frühzeitiges und vermehrtes Auftreten von bösartigen Erkrankungen – insbesondere AML und Plattenepitelkarzinome in der Kopf-Hals-Region (HNSCCs) und ano-genitalen Bereich – charakterisiert ist. Auf zellulärer Ebene prägen eine hohe genetische Instabilität und eine erhöhte Sensitivität gegenüber kreuzvernetzenden Substanzen die Erkrankung. Bisher wurden Keimbahnmutationen in 15 FA-Genen identifiziert, wobei einige FA-Gene identisch mit bekannten Suszeptibilitätsgenen für familiäre Tumorerkrankungen sind.

In den letzten 10 Jahren hat der Anteil der FA-Patienten, die bis ins Erwachsenenalter überlebt, deutlich zugenommen. Bei diesen Patienten treten HNSCCs sehr früh und häufig ohne die üblichen Risikofaktoren auf. Cisplatin-basierte Chemotherapie in Kombination mit Bestrahlung, die bei sporadischen HNSCCs Therapiestandard ist, kann selbst mit reduzierter Dosis bei FA-Patienten aufgrund der assoziierten Toxizität und Mortalität nicht angewendet werden. Deshalb ist die chirurgische Tumorentfernung die wichtigste Therapieoption bei FA-Patienten, die allerdings eine effiziente Früherkennung der malignen Läsionen voraussetzt. Da derzeit kein einheitliches Diagnostik- und Therapieoptimierungsprotokoll für HNSCCs bei FA-Patienten existiert, sind Informationen von betroffenen Patienten weltweit zu sammeln, therapeutische Leitlinien zu entwickeln und nationale Behandlungszentren zu etablieren.

Key words

Fanconi anemia - HNSCC - therapy - HPV - prevention

Schlüsselwörter

Fanconi-Anämie - Plattenepithelkarzinome - Therapie - HPV - - Prävention

• References

• 1 Alter BP. Radiosensitivity in Fanconi’s anemia patients. Radiother Oncol 2002; 62: 345-347
• 2 Alter BP. Fanconi’s anemia, transplantation, and cancer. Pediatr Transplant 2005; 9 (Suppl. 07) 81-86
• 3 Alter BP, Joenje H, Oostra AB et al. Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg 2005; 131: 635-639
• 4 Balz V, Scheckenbach K, Gotte K et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003; 63: 1188-1191
• 5 Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952
• 6 Bernier J, Pfister DG, Cooper JS. Adjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomas. Crit Rev Oncol Hematol 2005; 56: 353-364
• 7 Birkeland AC, Auerbach AD, Sanborn E et al. Postoperative clinical radiosensitivity in patients with fanconi anemia and head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2011; 137: 930-934
• 8 Block SL, Nolan T, Sattler C et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 2135-2145
• 9 Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578
• 10 Chaudhury S, Auerbach AD, Kernan NA et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol 2008; 140: 644-655
• 11 Compostella A, Toffolutti T, Soloni P et al. Multiple synchronous tumors in a child with Fanconi anemia. J Pediatr Surg 2010; 45: e5-e8
• 12 Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944
• 13 D’Souza G, Agrawal Y, Halpern J et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199: 1263-1269
• 14 D’Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956
• 15 de Araujo M, Rubira-Bullen I, Santos C et al. High prevalence of oral human papillomavirus infection in Fanconi’s anemia patients. Oral Dis 2011; 17: 572-576
• 16 Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011; 11: 467-480
• 17 Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403-426
• 18 Erkko H, Xia B, Nikkila J et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007; 446: 316-319
• 19 Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24: 2606-2611
• 20 Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269
• 21 Farzin A, Davies SM, Smith FO et al. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children’s experience. Br J Haematol 2007; 136: 633-640
• 22 Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937-5949
• 23 Han TJ, Lee CH, Yoo CW et al. Synchronous multifocal HPV-related neoplasm involving both the genital tract and the head-and-neck area: a case report of Fanconi anemia. Radiother Oncol 2009; 92: 138-141
• 24 Hoffmann TK, Sonkoly E, Hauser U et al. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 2008; 44: 1100-1109
• 25 Hosoya Y, Lefor A, Hirashima Y et al. Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia. Jpn J Clin Oncol. 2010 40. 805-810
• 26 Huck K, Hanenberg H, Gudowius S et al. Delayed diagnosis and complications of Fanconi anaemia at advanced age – a paradigm. Br J Haematol 2006; 133: 188-197
• 27 Huck K, Hanenberg H, Nürnberger W et al. Favourable long -term outcome after matched sibling transplantation for Fanconi anemia (FA) and in vivo T-cell depletion. Klin Padiatr 2008; 220: 147-152
• 28 Jerjes W, Upile T, Hamdoon Z et al. Photodynamic therapy outcome for T1/T2 N0 oral squamous cell carcinoma. Lasers Surg Med 2011; 43: 463-469
• 29 Jones S, Hruban RH, Kamiyama M et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217
• 30 Kero K, Rautava J, Syrjanen K et al. Human papillomavirus genotypes in male genitalia and their concordance among pregnant spouses participating in the Finnish Family HPV study. J Sex Med 2011; 8: 2522-2531
• 31 Kitao H, Takata M. Fanconi anemia: a disorder defective in the DNA damage response. Int J Hematol 2011; 93: 417-424
• 32 Koch FP, Kaemmerer PW, Biesterfeld S et al. Effectiveness of autofluorescence to identify suspicious oral lesions – a prospective, blinded clinical trial. Clin Oral Investig 2011; 15: 975-982
• 33 Koch FP, Kunkel M, Biesterfeld S et al. Diagnostic efficiency of differentiating small cancerous and precancerous lesions using mucosal brush smears of the oral cavity – a prospective and blinded study. Clin Oral Investig 2011; 15: 763-769
• 34 Kutler DI, Auerbach AD, Satagopan J et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003; 129: 106-112
• 35 Kutler DI, Singh B, Satagopan J et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249-1256
• 36 Kutler DI, Wreesmann VB, Goberdhan A et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003; 95: 1718-1721
• 37 Lavaf A, Genden EM, Cesaretti JA et al. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer 2008; 112: 535-543
• 38 Lee J, Moon C. Current status of experimental therapeutics for head and neck cancer. Exp Biol Med 2011; 236: 375-389
• 39 Macfarlane GJ, Zheng T, Marshall JR et al. Alcohol, tobacco, diet and the risk of oral cancer: a pooled analysis of three case-control studies. Eur J Cancer B Oral Oncol 1995; 31B: 181-187
• 40 MacMillan ML, Hughes MR, Agarwal S et al. Cellular therapy for fanconi anemia: the past, present, and future. Biol Blood Marrow Transplant 2011; 17: S109-S114
• 41 Marcou Y, D’Andrea A, Jeggo PA et al. Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. Radiother Oncol 2001; 60: 75-79
• 42 Masserot C, Peffault de Latour R, Rocha V et al. Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer 2008; 113: 3315-3322
• 43 Matta A, Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 2009; 1: 6
• 44 Mayne ST, Cartmel B, Kirsh V et al. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. Cancer Epidemiol Biomarkers Prev 2009; 18: 3368-3374
• 45 Mehrotra R, Gupta DK. Exciting new advances in oral cancer diagnosis: avenues to early detection. Head Neck Oncol 2011; 3: 33
• 46 Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-560
• 47 Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527
• 48 Offit K, Levran O, Mullaney B et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003; 95: 1548-1551
• 49 Park JW, Pitot HC, Strati K et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res 2010; 70: 9959-9968
• 50 Pennington KP, Swisher EM. Hereditary ovarian cancer: Beyond the usual suspects. Gynecol Oncol 2012; 124: 347-353
• 51 Psyrri A, Boutati E, Karageorgopoulou S. Human papillomavirus in head and neck cancers: biology, prognosis, hope of treatment, and vaccines. Anticancer Drugs 2011; 22: 586-590
• 52 Reid S, Renwick A, Seal S et al. Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J Med Genet 2005; 42: 147-151
• 53 Reinhard H, Peters I, Gottschling S et al. Squamous Cell Carcinoma of the Tongue in a 13-year-old Girl With Fanconi Anemia. J Pediatr Hematol Oncol 2007; 29: 488-491
• 54 Rodriguez T, Altieri A, Chatenoud L et al. Risk factors for oral and pharyngeal cancer in young adults. Oral Oncol 2004; 40: 207-213
• 55 Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003; 101: 822-826
• 56 Rosenberg PS, Socie G, Alter BP et al. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 2005; 105: 67-73
• 57 Rosenquist K, Wennerberg J, Schildt EB et al. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol 2005; 125: 1327-1336
• 58 Scheckenbach K, Morgan M, Filger-Brillinger J et al. Treatment of the bone marrow failure in Fanconi anemia patients with danazol. Blood Cells Mol Dis 2012; 48: 128-131
• 59 Scheffner M, Huibregtse JM, Vierstra RD et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505
• 60 Scheffner M, Werness BA, Huibregtse JM et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136
• 61 Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005; 92: 1341-1348
• 62 Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85
• 63 Spanier G, Pohl F, Giese T et al. Fatal course of tonsillar squamous cell carcinoma associated with Fanconi anaemia: A mini review. J Craniomaxillofac Surg 2011; online Sept. 17
• 64 Spardy N, Duensing A, Charles D et al. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J Virol 2007; 81: 13265-13270
• 65 Spardy N, Duensing A, Hoskins EE et al. HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies. Cancer Res 2008; 68: 9954-9963
• 66 St Guily JL, Jacquard AC, Pretet JL et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France – The EDiTH VI study. J Clin Virol 2011; 51: 100-104
• 67 Stepensky P, Shapira MY, Balashov D et al. Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning. Biol Blood Marrow Transplant 2011; 17: 1282-1288
• 68 Syrjanen K, Syrjanen S, Lamberg M et al. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983; 12: 418-424
• 69 Tan IB, Cutcutache I, Zang ZJ et al. Fanconi’s anemia in adulthood: chemoradiation-induced bone marrow failure and a novel FANCA mutation identified by targeted deep sequencing. J Clin Oncol 2011; 29: e591-e594
• 70 Tönnies H, Huber S, Kühl JS et al. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 2003; 101: 3872-3874
• 71 Tota JE, Chevarie-Davis M, Richardson LA et al. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 2011; 53 (Suppl. 01) S12-S21
• 72 van Zeeburg HJ, Snijders PJ, Joenje H et al. Re: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2004; 96: 968 author reply 968–969
• 73 van Zeeburg HJ, Snijders PJ, Pals G et al. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res 2005; 65: 1271-1276
• 74 van Zeeburg HJ, Snijders PJ, Wu T et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2008; 100: 1649-1653
• 75 Wagner JE, Eapen M, Macmillan ML et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007; 109: 2256-2262
• 76 Wagner JE, Tolar J, Levran O et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia and Fanconi anemia. Blood 2004; 103: 3226-3229